ENLARGE Lung: First Interim Primary Cohort Data (n = 660) from a National, Prospective, Non-Interventional Study (NIS) of Nivolumab (Nivo) after Prior Chemotherapy in Patients (pts) with Locally Advanced or Metastatic (Stage IIIB/IV) Squamous/Non-squamous Non-Small Cell Lung Cancer (NSCLC)

2019 ◽  
Author(s):  
M Sebastian ◽  
M Gröschel ◽  
S Gütz ◽  
H Schulz ◽  
K Kratz-Albers ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Locally Advanced ◽  
Small Cell ◽  
Stage Iiib ◽  
Small Cell Lung ◽  
Interventional Study ◽  
Prior Chemotherapy ◽  
Cohort Data

scholarly journals Real-world EGFR testing in patients with stage IIIB/IV non-small-cell lung cancer in North China: A multicenter, non-interventional study

2018 ◽  
Vol 9 (11) ◽  
pp. 1461-1469 ◽  
Author(s):  
Ying Cheng ◽  
Yan Wang ◽  
Jun Zhao ◽  
Yunpeng Liu ◽  
Hongjun Gao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
North China ◽  
Small Cell ◽  
Stage Iiib ◽  
Small Cell Lung ◽  
Interventional Study

Surgical Treatment of Initially Unresectable Locally Advanced Non-small Cell Lung Cancer Following Tislelizumab Plus Chemotherapy: A Case Report

2021 ◽  
Author(s):  
Chen Huang ◽  
Yongmei Dai ◽  
Qianshun Chen ◽  
Feng Li ◽  
Xunyu Xu
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Advanced Nsclc ◽  
Combined Treatment ◽  
Locally Advanced ◽  
Small Cell ◽  
Stage Iiib ◽  
Small Cell Lung ◽  
Locally Advanced Nsclc

Abstract Background: Radical concurrent chemoradiotherapy is the preferred treatment for patients with stage IIIB non-small cell lung cancer (NSCLC), but the prognosis is poor. The emergence of immune checkpoint inhibitors has changed the treatment strategy for advanced NSCLC, providing new opportunities for therapy. However, neoadjuvant immunotherapy of locally advanced NSCLC is still in the exploratory stage. Case presentation: A 47-year-old male with stage IIIB squamous cell lung cancer with invasion of the pulmonary artery, left superior pulmonary vein (LSPV), and left atrium (LA) at diagnosis. The patient’s lesions were significantly reduced after four cycles of combined treatment with tislelizumab and carboplatin plus nab-paclitaxel, he then underwent successful left pneumonectomy with mediastinal lymph node dissection, and postoperative pathology showed a pathologic complete response (pCR). Conclusions: The findings demonstrated that chemotherapy in combination with immunotherapy can provide an opportunity for radical surgery in some patients with locally advanced NSCLC.

Current and future therapeutic approaches in locally advanced (stage III) non[ndash ]small cell lung cancer

2002 ◽  
Vol 29 (3 Suppl 12) ◽  
pp. 10-16 ◽  
Author(s):  
Angela Davies ◽  
David R. Gandara ◽  
Primo Lara ◽  
Zelanna Goldberg ◽  
Peter Roberts ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Locally Advanced ◽  
Small Cell ◽  
Stage Iii ◽  
Advanced Stage ◽  
Therapeutic Approaches ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document